Status:
COMPLETED
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
Lead Sponsor:
Isofol Medical AB
Conditions:
Colorectal Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose is to characterise the tolerability of Modufolin (arfolitixorin) in combination with 5-FU alone, in combination with 5-FU and Oxaliplatin, in combination with 5-FU and Irinotecan and in co...
Detailed Description
The study will investigate the tolerability of Modufolin at four (4) different dose levels (30 to 240 mg/m2) in therapy combinations with the chemotherapeutic agents 5-FU, Oxaliplatin +/- bevcizumab, ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Advanced metastatic colorectal (Stage IV) cancer verified by biopsy
Exclusion
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2020
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT02244632
Start Date
September 1 2014
End Date
January 30 2020
Last Update
September 9 2020
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Odense University Hospital
Odense, Denmark
2
251 General Airforce Hospital
Athens, Greece
3
Medical School University of Athens, Aretaieio Hospital
Athens, Greece
4
Metropolitan General Hospital
Athens, Greece